These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Treatment of diverticular disease: an update on latest evidence and clinical implications. Carabotti M; Annibale B Drugs Context; 2018; 7():212526. PubMed ID: 29623099 [TBL] [Abstract][Full Text] [Related]
27. Mesalazine for diverticular disease of the colon--a new role for an old drug. Tursi A Expert Opin Pharmacother; 2005 Jan; 6(1):69-74. PubMed ID: 15709884 [TBL] [Abstract][Full Text] [Related]
28. Guidelines for Colonic Diverticular Bleeding and Colonic Diverticulitis: Japan Gastroenterological Association. Nagata N; Ishii N; Manabe N; Tomizawa K; Urita Y; Funabiki T; Fujimori S; Kaise M Digestion; 2019; 99 Suppl 1():1-26. PubMed ID: 30625484 [TBL] [Abstract][Full Text] [Related]
30. Recent advances in the treatment of colonic diverticular disease and prevention of acute diverticulitis. Elisei W; Tursi A Ann Gastroenterol; 2016; 29(1):24-32. PubMed ID: 26752946 [TBL] [Abstract][Full Text] [Related]
31. Diverticular Disease: A Review on Pathophysiology and Recent Evidence. Piscopo N; Ellul P Ulster Med J; 2020 Sep; 89(2):83-88. PubMed ID: 33093692 [TBL] [Abstract][Full Text] [Related]
32. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Brandimarte G; Tursi A Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281 [TBL] [Abstract][Full Text] [Related]
34. Diverticular disease: diagnosis and treatment. Špičák J; Kučera M; Suchánková G Vnitr Lek; 2018; 64(6):621-634. PubMed ID: 30223660 [TBL] [Abstract][Full Text] [Related]
35. [Role of rifaximin in the treatment of colonic diverticular disease]. Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232 [TBL] [Abstract][Full Text] [Related]
36. Novel swine model of colonic diverticulosis. Guo X; Patel B; Han L; Al-Dulaimi H; Van Alstine WG; Noblet JN; Chambers S; Kassab GS Am J Physiol Gastrointest Liver Physiol; 2019 Jul; 317(1):G51-G56. PubMed ID: 31091148 [TBL] [Abstract][Full Text] [Related]
37. Course of the Diverticular Disease: What is changing? Milosavljeviĉ T; Brandimarte G; Stollman N; Barbara G; Lahat A; Scarpignato C; Lanas A; Papa V; Tursi A; Nardone G J Gastrointestin Liver Dis; 2019 Dec; 28(suppl. 4):11-16. PubMed ID: 31930229 [TBL] [Abstract][Full Text] [Related]
38. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. Tursi A; Brandimarte G; Giorgetti GM; Elisei W J Clin Gastroenterol; 2006 Apr; 40(4):312-6. PubMed ID: 16633103 [TBL] [Abstract][Full Text] [Related]
39. Diverticular Disease: An Update on Pathogenesis and Management. Rezapour M; Ali S; Stollman N Gut Liver; 2018 Mar; 12(2):125-132. PubMed ID: 28494576 [TBL] [Abstract][Full Text] [Related]
40. Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon. Scaioli E; Colecchia A; Marasco G; Schiumerini R; Festi D Dig Dis Sci; 2016 Mar; 61(3):673-83. PubMed ID: 26458921 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]